Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 18 studies | 36% ± 12% | |
brain | 17 studies | 39% ± 20% | |
lung | 10 studies | 31% ± 9% | |
eye | 7 studies | 33% ± 12% | |
heart | 5 studies | 33% ± 9% | |
liver | 5 studies | 43% ± 16% | |
bone marrow | 4 studies | 28% ± 11% | |
kidney | 4 studies | 23% ± 2% | |
lymph node | 4 studies | 25% ± 7% | |
adipose | 4 studies | 35% ± 8% | |
uterus | 3 studies | 19% ± 3% | |
breast | 3 studies | 18% ± 2% | |
intestine | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3568.64 | 1445 / 1445 | 100% | 10.94 | 183 / 183 |
lung | 100% | 6451.57 | 578 / 578 | 100% | 9.10 | 1155 / 1155 |
breast | 100% | 4625.96 | 459 / 459 | 100% | 9.16 | 1117 / 1118 |
uterus | 100% | 3594.19 | 170 / 170 | 99% | 8.78 | 455 / 459 |
thymus | 100% | 3683.21 | 652 / 653 | 99% | 8.23 | 600 / 605 |
bladder | 100% | 3992.29 | 21 / 21 | 99% | 8.19 | 498 / 504 |
prostate | 100% | 3266.61 | 245 / 245 | 99% | 5.84 | 495 / 502 |
stomach | 100% | 3030.76 | 359 / 359 | 99% | 7.78 | 282 / 286 |
ovary | 100% | 4965.82 | 180 / 180 | 98% | 4.69 | 423 / 430 |
pancreas | 100% | 2212.43 | 328 / 328 | 98% | 7.74 | 175 / 178 |
intestine | 100% | 4012.41 | 966 / 966 | 98% | 7.44 | 515 / 527 |
adrenal gland | 100% | 4326.36 | 258 / 258 | 96% | 5.87 | 221 / 230 |
kidney | 100% | 2573.28 | 89 / 89 | 96% | 6.31 | 863 / 901 |
liver | 100% | 3154.62 | 226 / 226 | 93% | 4.31 | 377 / 406 |
brain | 92% | 1863.17 | 2439 / 2642 | 100% | 6.44 | 703 / 705 |
skin | 100% | 5024.55 | 1809 / 1809 | 88% | 6.81 | 416 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 10.56 | 29 / 29 |
muscle | 100% | 4482.39 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 9600.90 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.75 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.84 | 1 / 1 |
blood vessel | 100% | 4090.78 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 5188.66 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 13166.18 | 928 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 2874.57 | 831 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 41% | 1.80 | 33 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0140673 | Biological process | transcription elongation-coupled chromatin remodeling |
GO_0035520 | Biological process | monoubiquitinated protein deubiquitination |
GO_1990167 | Biological process | protein K27-linked deubiquitination |
GO_0030509 | Biological process | BMP signaling pathway |
GO_1900246 | Biological process | positive regulation of RIG-I signaling pathway |
GO_0006508 | Biological process | proteolysis |
GO_1902238 | Biological process | regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator |
GO_0016579 | Biological process | protein deubiquitination |
GO_1905035 | Biological process | negative regulation of antifungal innate immune response |
GO_0007179 | Biological process | transforming growth factor beta receptor signaling pathway |
GO_0005739 | Cellular component | mitochondrion |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0101005 | Molecular function | deubiquitinase activity |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0046332 | Molecular function | SMAD binding |
GO_0042802 | Molecular function | identical protein binding |
GO_1990380 | Molecular function | K48-linked deubiquitinase activity |
GO_0061649 | Molecular function | ubiquitin-modified histone reader activity |
GO_0005160 | Molecular function | transforming growth factor beta receptor binding |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | USP15 |
Protein name | Ubiquitin carboxyl-terminal hydrolase 15 (EC 3.4.19.12) (Deubiquitinating enzyme 15) (Ubiquitin thioesterase 15) (Ubiquitin-specific-processing protease 15) (Unph-2) (Unph4) ubiquitinyl hydrolase 1 (EC 3.4.19.12) Ubiquitin specific peptidase 15 |
Synonyms | KIAA0529 |
Description | FUNCTION: Hydrolase that removes conjugated ubiquitin from target proteins and regulates various pathways such as the TGF-beta receptor signaling, NF-kappa-B and RNF41/NRDP1-PRKN pathways . Acts as a key regulator of TGF-beta receptor signaling pathway, but the precise mechanism is still unclear: according to a report, acts by promoting deubiquitination of monoubiquitinated R-SMADs (SMAD1, SMAD2 and/or SMAD3), thereby alleviating inhibition of R-SMADs and promoting activation of TGF-beta target genes . According to another reports, regulates the TGF-beta receptor signaling pathway by mediating deubiquitination and stabilization of TGFBR1, leading to an enhanced TGF-beta signal . Able to mediate deubiquitination of monoubiquitinated substrates, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains . May also regulate gene expression and/or DNA repair through the deubiquitination of histone H2B . Acts as an inhibitor of mitophagy by counteracting the action of parkin (PRKN): hydrolyzes cleavage of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains attached by parkin on target proteins such as MFN2, thereby reducing parkin's ability to drive mitophagy . Acts as an associated component of COP9 signalosome complex (CSN) and regulates different pathways via this association: regulates NF-kappa-B by mediating deubiquitination of NFKBIA and deubiquitinates substrates bound to VCP . Involved in endosome organization by mediating deubiquitination of SQSTM1: ubiquitinated SQSTM1 forms a molecular bridge that restrains cognate vesicles in the perinuclear region and its deubiquitination releases target vesicles for fast transport into the cell periphery . Acts as a negative regulator of antifungal immunity by mediating 'Lys-27'-linked deubiquitination of CARD9, thereby inactivating CARD9 . .; FUNCTION: (Microbial infection) Protects APC and human papillomavirus type 16 protein E6 against degradation via the ubiquitin proteasome pathway. . |
Accessions | F8VZG8 ENST00000549237.5 H0YI31 H0YH96 ENST00000312635.10 [Q9Y4E8-4] H0YHM4 ENST00000546694.1 H0YI26 ENST00000548620.1 ENST00000549523.5 ENST00000353364.7 [Q9Y4E8-2] F8VVY7 Q9Y4E8 ENST00000552997.1 ENST00000280377.10 [Q9Y4E8-1] Q2NL66 F8W0H4 ENST00000548836.1 ENST00000549415.1 |